ReviewActa gastroenterologica Latinoamericana
[Therapeutic Developments in Eosinophilic Esophagitis].
Review in Acta gastroenterologica Latinoamericana. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence of Sensitization to Panallergens and IgG4 Profiles Against Specific Foods in Patients with Allergic-Phenotype Eosinophilic Esophagitis.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic esophagitis (EoE) is a chronic immunoallergic disorder caused, in most cases, by a non-IgE mediated food allergy. Its current prevalence exceeds 1 case per 1,000 inhabitants in Spain and Europe, while it is emerging in South America. This review attempts to update the therapeutic novelties that have appeared in the last 5 years for either induction or maintenance in this pathology, including new anti-acid drugs (potassium competitive acid blockers), simplified optimization of dietary schemes, novel swallowed topical corticosteroids specifically developed for esophageal delivery, as well as the incorporation of biologic agents into the therapeutic algorithm of the disease. Endoscopic dilation continues to be a safe and effective complement for symptomatic improvement, in combination with anti-inflammatory treatments for the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.